vs
CVRx, Inc.（CVRX）与SS Innovations International, Inc.（SSII）财务数据对比。点击上方公司名可切换其他公司
CVRx, Inc.的季度营收约是SS Innovations International, Inc.的1.1倍（$16.0M vs $14.5M），SS Innovations International, Inc.净利率更高（-17.0% vs -74.5%，领先57.5%），SS Innovations International, Inc.同比增速更快（79.1% vs 4.4%），SS Innovations International, Inc.自由现金流更多（$-3.2M vs $-9.8M），过去两年SS Innovations International, Inc.的营收复合增速更高（99.9% vs 22.0%）
CVRx, Inc.是一家处于商业化阶段的医疗科技企业，专注于慢性心血管疾病神经调节疗法的研发与商业化，旗舰产品Barostim系统用于治疗心力衰竭和难治性高血压，核心市场覆盖北美、欧洲，服务对常规药物治疗应答不佳的患者。
SS Innovations International, Inc.是一家全球化医疗科技企业，专注于研发、生产创新型外科手术机器人系统，为多地区医疗机构提供高精度、易获取的微创手术机器人平台，致力于提升手术效果、减轻手术操作负担。
CVRX vs SSII — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.0M | $14.5M |
| 净利润 | $-11.9M | $-2.5M |
| 毛利率 | 86.3% | 43.9% |
| 营业利润率 | -69.8% | -3.7% |
| 净利率 | -74.5% | -17.0% |
| 营收同比 | 4.4% | 79.1% |
| 净利润同比 | -12.0% | -28.5% |
| 每股收益（稀释后） | $-0.45 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $16.0M | $14.5M | ||
| Q3 25 | $14.7M | $12.8M | ||
| Q2 25 | $13.6M | $10.0M | ||
| Q1 25 | $12.3M | $5.1M | ||
| Q4 24 | $15.3M | $8.1M | ||
| Q3 24 | $13.4M | $4.4M | ||
| Q2 24 | $11.8M | $4.5M | ||
| Q1 24 | $10.8M | $3.6M |
| Q4 25 | $-11.9M | $-2.5M | ||
| Q3 25 | $-12.9M | $-3.7M | ||
| Q2 25 | $-14.7M | $-256.7K | ||
| Q1 25 | $-13.8M | $-5.7M | ||
| Q4 24 | $-10.7M | $-1.9M | ||
| Q3 24 | $-13.1M | $-3.2M | ||
| Q2 24 | $-14.0M | $-4.1M | ||
| Q1 24 | $-22.2M | $-9.8M |
| Q4 25 | 86.3% | 43.9% | ||
| Q3 25 | 86.8% | 48.1% | ||
| Q2 25 | 84.3% | 59.1% | ||
| Q1 25 | 83.5% | 21.2% | ||
| Q4 24 | 83.2% | 48.9% | ||
| Q3 24 | 83.2% | 52.8% | ||
| Q2 24 | 83.9% | 31.9% | ||
| Q1 24 | 85.0% | 20.0% |
| Q4 25 | -69.8% | -3.7% | ||
| Q3 25 | -83.5% | -14.3% | ||
| Q2 25 | -105.8% | 1.0% | ||
| Q1 25 | -108.8% | -115.6% | ||
| Q4 24 | -67.0% | -22.7% | ||
| Q3 24 | -97.3% | -73.1% | ||
| Q2 24 | -118.3% | -90.9% | ||
| Q1 24 | -206.4% | -270.3% |
| Q4 25 | -74.5% | -17.0% | ||
| Q3 25 | -87.6% | -29.0% | ||
| Q2 25 | -108.4% | -2.6% | ||
| Q1 25 | -111.5% | -111.0% | ||
| Q4 24 | -69.4% | -23.7% | ||
| Q3 24 | -98.0% | -74.0% | ||
| Q2 24 | -118.8% | -91.8% | ||
| Q1 24 | -206.0% | -270.5% |
| Q4 25 | $-0.45 | $-0.01 | ||
| Q3 25 | $-0.49 | $-0.02 | ||
| Q2 25 | $-0.57 | $0.00 | ||
| Q1 25 | $-0.53 | $-0.03 | ||
| Q4 24 | $-0.39 | $-0.01 | ||
| Q3 24 | $-0.57 | $-0.02 | ||
| Q2 24 | $-0.65 | $-0.02 | ||
| Q1 24 | $-1.04 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $75.7M | $3.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $39.3M | $38.2M |
| 总资产 | $104.8M | $74.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $75.7M | $3.2M | ||
| Q3 25 | $85.1M | $5.7M | ||
| Q2 25 | $95.0M | $11.4M | ||
| Q1 25 | $102.7M | $15.9M | ||
| Q4 24 | $105.9M | $466.5K | ||
| Q3 24 | $100.2M | $220.4K | ||
| Q2 24 | $70.4M | $608.2K | ||
| Q1 24 | $80.1M | $948.1K |
| Q4 25 | $39.3M | $38.2M | ||
| Q3 25 | $48.1M | $39.6M | ||
| Q2 25 | $57.9M | $42.0M | ||
| Q1 25 | $71.1M | $40.6M | ||
| Q4 24 | $71.1M | $13.5M | ||
| Q3 24 | $65.2M | $13.7M | ||
| Q2 24 | $55.2M | $14.8M | ||
| Q1 24 | $66.3M | $16.7M |
| Q4 25 | $104.8M | $74.2M | ||
| Q3 25 | $111.3M | $69.6M | ||
| Q2 25 | $119.6M | $70.0M | ||
| Q1 25 | $129.6M | $63.5M | ||
| Q4 24 | $133.4M | $42.4M | ||
| Q3 24 | $127.7M | $39.0M | ||
| Q2 24 | $96.0M | $35.7M | ||
| Q1 24 | $106.2M | $35.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-9.8M | $-1.5M |
| 自由现金流经营现金流 - 资本支出 | $-9.8M | $-3.2M |
| 自由现金流率自由现金流/营收 | -61.3% | -22.3% |
| 资本支出强度资本支出/营收 | 0.4% | 11.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-40.8M | $-22.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-9.8M | $-1.5M | ||
| Q3 25 | $-9.7M | $-7.5M | ||
| Q2 25 | $-7.9M | $-3.5M | ||
| Q1 25 | $-12.8M | $-6.1M | ||
| Q4 24 | $-8.0M | $-3.3M | ||
| Q3 24 | $-10.4M | $-2.5M | ||
| Q2 24 | $-9.8M | $-1.0M | ||
| Q1 24 | $-10.9M | $-2.7M |
| Q4 25 | $-9.8M | $-3.2M | ||
| Q3 25 | $-10.0M | $-8.2M | ||
| Q2 25 | $-8.0M | $-3.8M | ||
| Q1 25 | $-12.9M | $-7.0M | ||
| Q4 24 | $-8.1M | $-3.4M | ||
| Q3 24 | $-10.4M | $-4.2M | ||
| Q2 24 | $-10.2M | $-3.1M | ||
| Q1 24 | $-11.8M | $-2.8M |
| Q4 25 | -61.3% | -22.3% | ||
| Q3 25 | -68.1% | -64.1% | ||
| Q2 25 | -59.2% | -37.7% | ||
| Q1 25 | -104.3% | -136.2% | ||
| Q4 24 | -52.5% | -41.7% | ||
| Q3 24 | -78.1% | -96.9% | ||
| Q2 24 | -86.3% | -69.5% | ||
| Q1 24 | -109.7% | -76.9% |
| Q4 25 | 0.4% | 11.8% | ||
| Q3 25 | 2.0% | 5.9% | ||
| Q2 25 | 0.8% | 3.2% | ||
| Q1 25 | 0.9% | 17.0% | ||
| Q4 24 | 0.3% | 1.5% | ||
| Q3 24 | 0.3% | 38.8% | ||
| Q2 24 | 3.0% | 46.8% | ||
| Q1 24 | 8.5% | 3.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CVRX
| US | $14.9M | 93% |
| Other | $1.1M | 7% |
SSII
| System Sales | $13.4M | 92% |
| Other | $1.2M | 8% |
